Breast Cancer
Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer
CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...
- 2 years ago
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer
BROOKLYN, N.Y. & SHANGHAI - Accutar Biotechnology, Inc., a clinical stage biotechnology company focu...
- 3 years ago
